±üÌîÀèÀ¸¤Î¥³¥é¥à

¥ª¥¯¥Î¥¯¥ê¥Ë¥Ã¥¯¸ø¼°¥µ¥¤¥È

Ĺ°ú¤¯Äˤߤθ¶°ø¤Ï¡¢·ì´É¤¬9³ä

±üÌîÀèÀ¸¤Î¥³¥é¥à

¿ÇÎÅÆâÍÆ¡¦ÎÁ¶â¤Ë¤Ä¤¤¤Æ

¥¯¥ê¥Ë¥Ã¥¯¾Ò²ð
¡ÚOkuno Clinic. Åìµþ ¥ß¥Ã¥É¥¿¥¦¥óÁ°¡Û
¢©106-0032
ÅìµþÅÔ¹Á¶èÏ»ËÜÌÚ7-8-4¡¡¶äÎæ¥Ó¥ë4F
TEL¡§0120-305-598
¡ÚOkuno Clinic. Åìµþ Çò»³¡Û
¢©113-0001
ÅìµþÅÔʸµþ¶èÇò»³1-33-16¡¡¥Ñ¡¼¥¯¥³¡¼¥È¥×¥ì¥¤¥¹¥Ó¥ë3F
TEL¡§0120-305-598
¡ÚOkuno Clinic. ²£ÉÍ ¥»¥ó¥¿¡¼Æî¡Û
¢©224-0032
¿ÀÆàÀ²£ÉÍ»ÔÅÔÃÞ¶è³ý¥öºêÃæ±û36-6¡¡¥Û¥Æ¥ë¥¢¥È¥é¥¹2F
TEL¡§0120-305-598
°åÎŽ¾»ö¼Ô¤ÎÊý¤Ø
¥³¥é¥à¥«¥Æ¥´¥ê¡¼
±¿Æ°´ï¥«¥Æ¡¼¥Æ¥ë¼£ÎŤȤϡ©
ÏÀʸ¤Î¾Ò²ð
¥á¥Ç¥£¥¢·ÇºÜ
¡Ö¸ª¡¢Éª¡¢¼ê¤ÎÄˤߡפˤĤ¤¤Æ¤Î¥³¥é¥à
¡Ö¤Ò¤¶¡¢Â­¡¢¤½¤Î¾¤ÎÄˤߡפˤĤ¤¤Æ¤Î¥³¥é¥à
±üÌî¥Ö¥í¥°

ÏÀʸ¤Î¾Ò²ð

±üÌîÀèÀ¸¤ÎÆüËܸìÏÀʸ¡¡¸ª¤ÎÌë´ÖÄˤؤΥ«¥Æ¡¼¥Æ¥ë¼£ÎÅ




±üÌîÀèÀ¸¤ÎÆüËܸìÏÀʸ¡¡¸ª¤ÎÌë´ÖÄˤؤΥ«¥Æ¡¼¥Æ¥ë¼£ÎÅ



ËýÀ­Åª¤Ê¸ª´ØÀá¤ÎÌë´ÖÄˤËÂФ¹¤ë·Ðư̮ŪÈù¾®·ì´ÉºÉÀòÎÅË¡¤ÎÍ­¸úÀ­


¡Ú¤Ï¤¸¤á¤Ë¡Û

¸ª´ØÀá¤ÎÌë´ÖÄˤϻþ¤Ë·ãÎõ¤È¤Ê¤ê¡¢ºÂ¤Ã¤¿¤Þ¤Þ¤Î½¢¿²¤ò;µ·¤Ê¤¯¤µ¤ì¤ëÎã¤äÃø¤·¤¯¿ç̲¤¬¾ã³²¤µ¤ì¤ë¥±¡¼¥¹¤â¿¤¯»¶¸«¤µ¤ì¤ë¡£°ìÈÌ¿ÇÎŤÇÉÑÈˤËÁø¶ø¤¹¤ë¾É¾õ¤Ç¤¢¤ë¤â¤Î¤Î¡¢¤½¤ÎȯÀ¸µ¡½ø¤Ë¤Ä¤¤¤Æ¤Ï¹üÆâ°µ¤Î¾å¾º17)¡¢¸ªÊö²¼³ê±ÕÊñ¤Î°µ¾å¾º14)¡¢¶ÚÆù¤ÎÚ»½Ì8)¤Ê¤É¤¬Ä󾧤µ¤ì¤Æ¤¤¤ë¤¬Ì¤¤À¤ËÅý°ì¤·¤¿¸«²ò¤ÏÆÀ¤é¤ì¤Æ¤¤¤Ê¤¤¡£¸ª´ØÀá¤ÎÌë´ÖÄˤϡּ«Á³¤Ë·Ú²÷¤¹¤ë(Self-limiting)¡×¤Èɽ¸½¤µ¤ì¤ë¤³¤È¤â¤¢¤ë¤¬¡¢¼ï¡¹¤Î¼£ÎÅË¡¤ËÄñ¹³¤·¿ôǯ¤Ë¤ï¤¿¤ê´µ¼Ô¤ò¶ì¤·¤á¤ë¥±¡¼¥¹¤â¾¯¤Ê¤¯¤Ê¤¤¡£

ºÇ¶á¤Ë¤Ê¤Ã¤Æ¡¢ËýÀ­Åª¤ÊáÖÄËÁÈ¿¥¤Ë¤ª¤±¤ëÁÈ¿¥³ØŪ¸¡Æ¤¤«¤éÈù¾®¤Ê·ì´ÉÁý¿£¤È¤½¤ì¤ËȼÁö¤¹¤ë¿À·ÐÀþ°Ý¤ÎÁý¿£¤¬»ØŦ¤µ¤ì¤Æ¤­¤¿5,6,11,16)¡£¤³¤ì¤é¤¬áÖÄˤθ¶°ø¤È¤Ê¤Ã¤Æ¤¤¤ë¤È¤Î²¾Àâ¤Î¤â¤È¤Ë²æ¡¹¤ÏÊݸÎÅË¡¤ËÄñ¹³¤¹¤ë¸ª´ØÀá¼þ°Ï±ê¤Î´µ¼Ô¤Ë·Ðư̮ŪÈù¾®·ì´ÉºÉÀòÎÅË¡transcatheter arterial micro-embolization (TAME)¤ò¹Ô¤¤¤½¤Î·ë²Ì¤òÊó¹ð¤·¤¿7¡Ë¡£ËÜÏÀʸ¤ÎÃæ¤ÇÉ®¼Ô¤é¤Ï¡¢¸ª´ØÀá¼þ°Ï±ê¤Î´ØÀáÊñ¤äç§ÈÄÁÂÉô¤ËÀµ¾ï¤Ç¤¢¤ì¤Ð¸«¤é¤ì¤Ê¤¤ÈùºÙ¤Ê°Û¾ï·ì´É¤¬´Ñ»¡¤Ç¤­¤ë¤È¤·¡¢¤µ¤é¤Ë¤³¤ì¤é¤ÎÈùºÙ¤Ê·ì´É¤òɸŪ¤È¤·¤ÆÆ°Ì®Æ⤫¤é°ì»þŪ¤ÊºÉÀòʪ¼Á¤òÅêÍ¿¤¹¤ë¤³¤È¤Ç¸ú²ÌŪ¤Ê½üÄˤ¬ÆÀ¤é¤ì¤¿¤ÈÊó¹ð¤·¤Æ¤¤¤ë¡£ÆäËÌë´ÖÄˤϼ£ÎŸåÁá´ü¤Ë²þÁ±¤·¤¿¤ÈÊó¹ð¤·¤¿¡£¤·¤«¤·¸ª´ØÀá¼þ°Ï±ê°Ê³°¤ÎËýÀ­Åª¤Ê¸ª´ØÀá¤ÎÌë´ÖÄˤòɸŪ¤Ë¤·¤¿¼£ÎŤˤĤ¤¤Æ¤Ï¸¡Æ¤¤µ¤ì¤Æ¤¤¤Ê¤¤¡£

º£²ó²æ¡¹¤Ï¸ª´ØÀá¼þ°Ï±ê¤Ë¸Â¤é¤º¡¢ËýÀ­Åª¤Ê¸ª´ØÀá¤ÎÌë´ÖÄˤËÂФ·¤Æ·Ðư̮ŪÈù¾®·ì´ÉºÉÀòÎÅË¡(TAME)¤ò¹Ô¤Ê¤¤¤½¤Î¸ú²Ì¤ò¸¡Æ¤¤·¤¿¤Î¤ÇÊó¹ð¤¹¤ë¡£

¡ÚÂоݤÈÊýË¡¡Û

Ëܸ¦µæ¤ÏÅö»ÜÀߤÎÎÑÍý°Ñ°÷²ñ¤Î¾µÂú¤Î¤â¤È¤Ë¹Ô¤Ê¤Ã¤¿¡£
¡ÖÌë´ÖÄˤ¢¤ê¡×¤ÎÄêµÁ¤Ï¡¢´µ¼Ôµ­Æþ¼°¥¢¥ó¥±¡¼¥È¤Ë¤ª¤¤¤Æ¡ÖÌ뿲¤Æ¤¤¤ÆÄˤߤǵ¯¤­¤Æ¤·¤Þ¤¦¤³¤È¤¬¤¢¤ê¤Þ¤¹¤«¡©¡×¤ª¤è¤Ó¡ÖÄ«µ¯¤­¤¿»þ¤Ë¶¯¤¯Äˤळ¤È¤Ï¤¢¤ê¤Þ¤¹¤«¡©¡×¤Î£²¤Ä¤Î¼ÁÌä¤Ë¡Ö¤Ê¤¤/¤¿¤Þ¤Ë¤¢¤ë/¤¢¤ë¡×¤Î£³¤Ä¤ÎÁªÂò»è¤ÇÅú¤¨¤Æ¤â¤é¤¤¡¢¾¯¤Ê¤¯¤È¤â¤É¤Á¤é¤«°ìÊý¤Î¼ÁÌä¤Ë¤ª¤¤¤Æ¡Ö¤¢¤ë¡×¤òÁªÂò¤·¤¿¤â¤Î¤È¤·¤¿¡£

Ëܸ¦µæ¤ÎŬ±þ¾ò·ï¤Ï­¡ÊݸÎÅË¡¤ò¼õ¤±¤Æ¤¤¤ë¤Ë¤â´Ø¤ï¤é¤ºÌë´ÖÄˤ¬3¥ö·î°Ê¾å·Ñ³¤·¤Æ¤¤¤ë´µ¼Ô¤Ç¡¢­¢Visual Analog Scale (VAS) ¡æ50mm¤ÎÌë´ÖÄˤ¬¤¢¤ë´µ¼Ô¡¢­£¸¦µæ¤Î¼ñ»Ý¤Ë¤Ä¤¤¤ÆËܿͤ«¤é½ñÌ̤ÇƱ°Õ¤Î°Õ»Ö¤¬ÆÀ¤é¤ì¤¿´µ¼Ô¡¢­¤£¶¥ö·î´Ö¤Î½Ñ¸å·Ð²á´Ñ»¡¤¬²Äǽ¤Ê´µ¼Ô¤È¤·¤¿¡£½ü³°´ð½à¤Ï¡¢­¡¼ê½ÑÎÅË¡¤ÎŬ±þ¤Î¤¢¤ëç§ÈÄÃÇÎö¤òÍ­¤¹¤ë´µ¼Ô­¢½ÅÅÙ¤ÎÆ°Ì®¹Å²½¾É¤òÍ­¤¹¤ë´µ¼Ô¡¢­£Ç¾¹¼ºÉ¸å¸å°ä¾É¡¢´ØÀá¥ê¥¦¥Þ¥Á¡¢ÂÓ¾õá׿¾¸åáÖÄË¡¢´¶À÷¾É¡¢°­À­¿·À¸Êª¤òÍ­¤¹¤ë´µ¼Ô¡¢­¤Ç¯Îð¡æ£¸£°ºÐ¡¢¡ã£²£°ºÐ¤Î´µ¼Ô¡¢­¥¤½¤Î¤Û¤«°å»Õ¤¬Ëܼ£ÎŤò»Ü¹Ô¤¹¤ë¤Î¤ËŬÀڤǤʤ¤¤ÈȽÃǤ·¤¿´µ¼Ô¤È¤·¤¿¡£

ÂоݤÏ17¸ª¡¢16̾¡ÊÃËÀ­5̾¡Ë¤Ç¤¢¤Ã¤¿¡£

Ê¿¶ÑǯÎð¤Ï56.0ºÐ¡Ê40-76¡Ë¤Ç¤¢¤Ã¤¿¡££µÌ¾¤¬ÅüǢɤò¹çÊ»¤·¤Æ¤¤¤¿¡£
Ê¿¶Ñ¤ÎáÖÄË´ü´Ö¤Ï37¥ö·î¡Ê5¥ö·î¡Ý18ǯ¡Ë¤Ç¤¢¤ê¡¢1ǯ̤Ëþ¤¬8¸ª¡¢1ǯ°Ê¾å¤¬9¸ª¤Ç¤¢¤Ã¤¿¡£

Î×¾²Åª¿ÇÃǤÎÆâÌõ¤Ï¸ª´ØÀá¼þ°Ï±ê6¸ª¡¢¸ªÊö²¼¥¤¥ó¥Ô¥ó¥¸¥á¥ó¥È¾É¸õ·²7¸ª¡¢¼ê½ÑŬ±þ¤Î¤Ê¤¤ç§ÈÄÃÇÎö£²¸ª¡¢¸ª¹Ã¾å³Ñ±ê£±¸ª¡¢¸ª¹Ã¹ü¹üÀÞ¸å¤ÎÁ«±äÀ­áÖÄË£±¸ª¤Ç¤¢¤Ã¤¿¡£²áµî¤Ë¼õ¤±¤¿ÊݸÎÅË¡¤Ë¤Ä¤¤¤Æ¤ÏNSAIDsÆâÉþ¤¬13̾¡¢¥×¥ì¥¬¥Ð¥ê¥óÆâÉþ£·Ì¾¡¢¥È¥é¥Þ¥É¡¼¥ëÆâÉþ£µÌ¾¡¢¥¹¥Æ¥í¥¤¥ÉÌô¤Î´ØÀáÆâÃí¼Í14̾¡¢±¿Æ°ÎÅË¡10̾¤Ç¤¢¤Ã¤¿¡£½ÑÁ°¤ÎÄˤߤÎÀ­¼Á¤Ï¡¢¥º¥­¥º¥­£¹Ì¾¡¢¥¸¥ó¥¸¥ó£¶Ì¾¡¢½Å¤¤£¶Ì¾¡¢¥º¥­¥ó¥º¥­¥ó£³Ì¾¡¢¤À¤ë¤¤£²Ì¾¡¢¥Á¥¯¥Á¥¯£±Ì¾¡¢¥Ô¥ê¥Ô¥ê£±Ì¾¡¢¾Æ¤±¤ë¤è¤¦¤Ê£°Ì¾¡¢¥­¥ê¥­¥ê£°Ì¾¡¢¡ÊÊ£¿ô²óÅú²Ä¡Ë¤Ç¤¢¤Ã¤¿¡£

¡Ú·Ðư̮ŪÈù¾®·ì´ÉºÉÀòÎÅË¡(TAME)¡Û
¶É½êËã¿ì²¼¤ËÜö¹üÆ°Ì®¡Ê£±£³¸ª¡Ë¤Þ¤¿¤ÏÂçÂÜÆ°Ì®¡Ê£´¸ª¡Ë¤Î¤¤¤º¤ì¤«¤òÀü»É¤·¤¿¡£Àü»ÉÉô¤«¤é£³Fr Sheath Introducer¤òÁÞÆþ¤·¤¿¡££³£Æ£ò¤±Æ¥«¥Æ¡¼¥Æ¥ë¤òÁÞÆþ¤·æþãÝÆ°Ì®¤Þ¤Ç¿Ê¤á¤Æ¡¢¶»¸ªÊöÆ°Ì®¡¢Á°¾åÏÓ²óÀûÆ°Ì®¡¢¸å¾åÏÓ²óÀûÆ°Ì®¡¢¸ª¹Ã²óÀûÆ°Ì®¡¢¸ª¹Ã¾åÆ°Ì®¡¢æþãÝÆ°Ì®¤«¤é¤ÎľÀÜʬ´ô»Þ¤Î£¶Ëܤηì´É¤Ë¤Ä¤¤¤Æ¤±ÆºÞ¤òÍѤ¤¤ÆÁªÂòŪ·ì´É»£±Æ¤ò¹Ô¤Ê¤Ã¤¿¡£¸ª¹Ã¾å³Ñ±ê¤Î£±Îã¤Ë¤Ä¤¤¤Æ¤ÏϾ·ÛÆ°Ì®¤È·Û²£Æ°Ì®¤òÁªÂòŪ¤Ë·ì´É¤±Æ¤·¤¿¡£°Û¾ï·ì´É¤¬´Ñ»¡¤µ¤ì¤¿¾ì¹ç¤Ï¡¢ºÉÀòʪ¼Á¤ÎÅêÍ¿¤ò¹Ô¤Ê¤Ã¤¿¡£ºÉÀòʪ¼Á¤È¤·¤Æ¤Ï¥¤¥ß¥Ú¥Í¥à¡¦¥·¥é¥¹¥¿¥Á¥ó0.5g¤ò¤±ÆºÞ10£ã£ã¤Ë·üÂù¤·¤¿¤â¤Î¤ò£°¡¥£²£í£ì¤º¤ÄÅêÍ¿¤·¤¿¡£¥¤¥ß¥Ú¥Í¥à¡¦¥·¥é¥¹¥¿¥Á¥ó¤Ï¹³À¸Êª¼Á¤Ç¤¢¤ë¤¬¡¢¤½¤ÎÆñÍÏÀ­¤ÎÀ­¼Á¤«¤é°ìÄê»þ´ÖÍϤ±¤º¤Ë·ë¾½¹½Â¤¤òÊݤĤ³¤È¤¬ÃΤé¤ì¤Æ¤¤¤ë1)¡£¤³¤ÎÀ­¼Á¤òÍøÍѤ·¤Æ¾Ã²½´É¼ðá礫¤é¤ÎÀ÷¤ß½Ð¤¹¤è¤¦¤ÊOosingÀ­¤Î½Ð·ì¤Ê¤É¤ÎºÝ¤Ë»ß·ìºÞ¤È¤·¤ÆÍѤ¤¤é¤ì¤Æ¤­¤¿·Ð°Þ¤¬¤¢¤ë12)¡£ºÉÀòʪ¼Á¤ÎÅêÍ¿¸å¤Ë°Û¾ï·ì´É¤Î·ìή¸º¾¯¤òǧ¤á¤¿¤È¤³¤í¤Ç¼£ÎŽªÎ»¤È¤·¤¿¡£¥«¥Æ¡¼¥Æ¥ë¤òÈ´µî¤·¤ÆÆ°Ì®Àü»ÉÉô¤ò£±£°Ê¬´ÖÍѼ갵Ç÷»ß·ì¤·¤¿¡££±»þ´Ö¤Î°ÂÀŤθå¤Ë»ß·ì¤ò³Îǧ¤·¤ÆÅöÆüµ¢Âð¤È¤·¤¿¡Ê¹³¶Å¸ÇºÞÆâÉþ»þ¤Ï£²»þ´Ö¤Î°ÂÀŸå¤Ëµ¢Âð¤È¤·¤¿¡Ë¡£

¡Úɾ²Á¡Û
Ìë´ÖÄËVAS¡¢¤ª¤è¤Ó¼ç´ÑŪ¤Ê¿ç̲¤Î¼Á¤ÎÊѲ½¡Ê°­²½¡¢²þÁ±¤Ê¤·¡¢¾¯¤·²þÁ±¡¢ÃæÄøÅÙ²þÁ±¡¢ÂçÉý¤Ë²þÁ±¡¢¤Î£µ¤Ä¤«¤é´µ¼ÔÁªÂò¡Ë¤ò¼£ÎŸå1½µ¡¢4½µ¡¢12½µ¡¢24½µ¤ÇÄ´¤Ù¤¿¡£Ìë´ÖÄˤÎÉÑÅÙ¡Ê·î¤Ë£±Åٰʲ¼¡¢½µ¤Ë£±ÅÙ¡¢½µ¤ËȾʬ¡¢¤Û¤ÜËèÆü¡¢ËèÆüɬ¤º¡¢¤Î£µ¤Ä¤«¤é´µ¼ÔÁªÂò¡Ë¤ò¼£ÎŸå4½µ¡¢12½µ¡¢24½µ¤ÇÄ´¤Ù¤¿¡£
¹çÊ»¾É¤Î̵ͭ¤òÄ´¤Ù¤¿¡£

¡Ú¸åÎÅË¡¡Û
º£¤Þ¤Ç¤Ë¼õ¤±¤Æ¤¤¤¿ÊݸÎÅË¡¤Ë¤Ä¤¤¤Æ¤Ï¡¢´µ¼Ô¤¬´õ˾¤¹¤ì¤Ð¼£ÎŸå¤â·Ñ³¤¹¤ë¤³¤È¤òµö²Ä¤·¤¿¡£¤Þ¤¿¡¢·Ð²á´Ñ»¡´ü´ÖÃæ¤Î¿·¤¿¤Ê¼£ÎÅË¡¤ÎÄɲäˤĤ¤¤Æ¤Ïµö²Ä¤·¤Ê¤«¤Ã¤¿¡£


¡Ú·ë²Ì¡Û
17¸ªÁ´¤Æ¤Ë¤ª¤¤¤ÆÁªÂòŪư̮»£±Æ¤Ç°Û¾ï·ì´É¤òǧ¤á¤¿¡£
¿Þ1-3¤ËÂåɽŪ¤Ê·ì´É»£±Æ½ê¸«¤ò¤Þ¤È¤á¤¿¡£

°Û¾ï·ì´É¤¬Ç§¤á¤é¤ì¤¿Æ°Ì®¤Ï¡¢¶»¸ªÊöÆ°Ì®£¹¸ª¡¢Á°¾åÏÓ²óÀûÆ°Ì®£·¸ª¡¢¸å¾åÏÓ²óÀûÆ°Ì®£±¸ª¡¢¸ª¹Ã²óÀûÆ°Ì®£²¸ª¡¢¸ª¹Ã¾åÆ°Ì®£³¸ª¡¢æþãÝÆ°Ì®¤«¤é¤ÎľÀÜʬ´ô»Þ£µ¸ª¡¢Ï¾·ÛÆ°Ì®£±¸ª¡¢·Û²£Æ°Ì®£±¸ª¤Ç¤¢¤Ã¤¿¡£

°Û¾ï·ì´É¤Îǧ¤á¤é¤ì¤¿Éô°Ì¤Ï¡¢ç§ÈÄÁÂÉô¤¬£±£³¸ª¤ÈºÇ¤â¿¤¯¡¢Â³¤¤¤Æ·ëÀá´Ö¹Â£¶¸ª¡¢¸ªÊö²¼³ê±ÕÊñ£´¸ª¡¢Á°Êý´ØÀáÊñ£´¸ª¡¢¸åÊý´ØÀáÊñ£²¸ª¡¢æþãÝǹ£³¸ª¡¢¸ª¹Ã¾å³Ñ¼þ°Ï£±¸ª¤Ç¤¢¤Ã¤¿¡£¤Þ¤¿17¸ªÃæ12¸ª¤Ë¤ª¤¤¤Æ¡¢ÅêÍ¿¤·¤¿Â¤±ÆºÞ¤¬¶Ë¤á¤ÆÁá´ü¤ËÀÅÌ®¤ËήÆþ¤¹¤ë¸½¾Ý¡ÊEarly venous filling¡Ë¤òǧ¤á¤¿¡Ê¿Þ1-3¡Ë¡£

¼£ÎŤËȼ¤¦¹çÊ»¾É¤Ë¤Ä¤¤¤Æ¤Ï¡¢Àü»É¤·¤¿Üö¹üÆ°Ì®¤ÎÚ»½Ì¡ÊÆ°Ì®¤¬Ú»½Ì¤·Ã»»þ´Ö¥«¥Æ¡¼¥Æ¥ë¤¬Æ°¤«¤»¤Ê¤¯¤Ê¤ë¾õÂ֡ˤò£±Îã¤Ëǧ¤á¤¿¡Ê¥Ë¥È¥íÀ½ºÞ¤ÎÅêÍ¿¤Ë¤Æ²ò½ü¤µ¤ì¤¿¡Ë¤¬¡¢¤½¤Î¤Û¤«¤Î¹çÊ»¾É¤Ïǧ¤á¤Ê¤«¤Ã¤¿¡£

Ê¿¶ÑÌë´ÖÄËVAS¤Ï¼£ÎÅÁ°¡§72mm ¡Þ 7 mm¡¢¼£ÎŸå1½µ¡¢4½µ¡¢12½µ¡¢24½µ¤Ç¤½¤ì¤¾¤ì42 ¡Þ 26 mm, 28 ¡Þ 22 mm, 19 ¡Þ 24 mm, and 16 ¡Þ 23 mm¤Ç¤¢¤Ã¤¿¡Ê¿Þ4¡Ë¡£¿ç̲¤Î¼Á¤ÎÊѲ½¡¢Ìë´ÖÄˤÎÉÑÅÙ¡¢Â¾¤ÎÊݸÎÅË¡¤Î»ÈÍѾõ¶·¤òɽ£±¤Ë¤Þ¤È¤á¤¿¡£




¡Ú¾ÉÎ㶡Í÷¡Û

¾ÉÎ㣱¡§60ºÐ,½÷À­

¼çÁÊ¡§º¸¸ª¤ÎÌë´ÖÄË
´û±ýÎò¡§ÅüÇ¢ÉÂ
¸½ÉÂÎò¡§1ǯÁ°¤è¤êͶ°ú¤Ê¤¯º¸¸ªÄˤ¬½Ð¸½¤·¤¿¡£Ìë´Ö¤Ë¤Ê¤ë¤ÈáÖÄˤ¬Áý¤·¡¢ÄˤߤΤ¿¤á¤Ë£²»þ´Ö°Ê¾å̲¤ë¤³¤È¤¬º¤Æñ¤Ê¾õÂ֤Ȥʤä¿¡£ÆâÉþÌô¤äÃí¼Í¡¢ïª¡¢¥Þ¥Ã¥µ¡¼¥¸¤Ç¼£ÎŤò»î¤ß¤¿¤¬²þÁ±¤»¤ºÅö±¡¤ò¼õ¿Ç¤·¤¿¡£

½é¿Ç»þ¤ÎÆâÉþÌô¡§Pregabalin:150mg¡¢Duloxetin40mg¡¢Metformin750mg

¸½¾É¡§°ÂÀÅ»þVAS¤Ï51mm¡¢Æ°ºî»þ¤ÎVAS¤Ï85mm¡¢Ìë´Ö»þVAS¤Ï82mm¤Ç¤¢¤Ã¤¿¡£Ìë´ÖÄˤÎÉÑÅ٤ϡÖËèÆüɬ¤º¡×¡£Ìë´ÖÄˤˤĤ¤¤ÆËܿͤÎɽ¸½¤Ç¤Ï¡ÖÏÓ¤ò¤É¤Î°ÌÃÖ¤ËÃÖ¤¤¤¿¤é¤¤¤¤¤Î¤«¤ï¤«¤é¤Ê¤¯¤Ê¤ê¡¢¼«Ê¬¤ÎÏÓ¤òÀÚ¤êÍî¤È¤·¤Æ¿·¤·¤¤ÏӤ˼è¤êÂؤ¨¤¿¤¯¤Ê¤ë¤è¤¦¤ÊÄˤߡפǤ¢¤ê¡¢ÄˤߤÎÀ­¼Á¤Ï¡Ö¥º¥­¥º¥­¡×¤È¡Ö¥Á¥¯¥Á¥¯¡×¤òÁªÂò¤·¤¿¡£

¾³Ð½ê¸«¡§¸ª´ØÀá²ÄÆ°°è¤ÏÁ°Êýµó¾å150ÅÙ¡¢³°Àû50ÅÙ¡¢ÆâÀûTh10¥ì¥Ù¥ë¡¢XÀþ¸¡ºº¤Ç¤Ï°Û¾ï½ê¸«¤Ê¤·¡£Ä¶²»Çȸ¡ºº¤Ë¤ª¤¤¤ÆÌÀ¤é¤«¤Êç§ÈÄÃÇÎö¤òǧ¤á¤Ê¤«¤Ã¤¿¡£¿ÈÂν긫¤Ç¤Ï¸ª´ØÀáÁ°Êý¡¢±¨¸ýÆ͵¯¼þÊդ˰µÄˤòǧ¤á¤¿¡£HawkinsÍÛÀ­¡¢NeerÍÛÀ­¤Ç¤¢¤Ã¤¿¡£

Î×¾²¿ÇÃÇ¡§¸ªÊö²¼¥¤¥ó¥Ô¥ó¥¸¥á¥ó¥È¾É¸õ·²

·ì´É»£±Æ½ê¸«¡§¸ª¹Ã¾åÆ°Ì®¤«¤é¸ª´ØÀáÊñ¤ÎÁ°Ì̤ª¤è¤Ó¾åÊý¤Î°Û¾ï·ì´É¤òǧ¤á¤¿¡Ê¿Þ2¡Ë¡£Á°¾åÏÓ²óÀûÆ°Ì®¤«¤é¤Ï·ëÀá´Ö¹Â¤Ë°Û¾ï·ì´É¤¬´Ñ»¡¤µ¤ì¤¿¡£

¼£ÎŸå·Ð²á¡§¼£ÎÅÅöÆü¤«¤éÌë´ÖÄˤβþÁ±¤ò¼«³Ð¤·¤¿¡£Ìë´ÖÄËVAS¤Ï¼£ÎŸ壱½µ¡¢4½µ¡¢12½µ¡¢24½µ¤½¤ì¤¾¤ì¤Ë¤ª¤¤¤Æ21mm¡¢10mm¡¢0mm¡¢0mm¤Ç¤¢¤Ã¤¿¡£¼ç´ÑŪ¤Ê¿ç̲¤Î¼Á¤ÎÊѲ½¤Ï¼£ÎÅ£±½µ¸å¤Ë¡ÖÂçÉý¤Ë²þÁ±¡×¤Ç¤¢¤ê24½µ¤Þ¤ÇÉÔÊѤǤ¢¤Ã¤¿¡£Ìë´ÖÄˤÎÉÑÅ٤ϼ£ÎÅ4½µ¸å¤Ë¤ª¤¤¤Æ¡Ö½µ¤Ë£±Å١פǤ¢¤ê¡¢¼£ÎÅ24½µ¸å¤Ë¤Ï¡Ö·î¤Ë£±Åٰʲ¼¡×¤Ç¤¢¤Ã¤¿¡£


¾ÉÎ㣲¡§61ºÐ¡¡ÃËÀ­

¼çÁÊ¡§18ǯÁ°¤«¤é¤Î±¦¸ªÌë´ÖÄË

´û±ýÎò¡§ÅüǢɡ¢¹â·ì°µ

¸½ÉÂÎò¡§18ǯÁ°¤«¤é±¦¸ª¤ÎÄˤߤȷý¾åº¤Æñ¤¢¤ê¡£ÆäËÌë´Ö¤Ë¤Ê¤ë¤ÈÄˤߤ¬¶¯¤¯¤Ê¤ê¡¢ÏÓ¤ÎÃÖ¤­¾ì½ê¤Ëº¤¤ë¡£¥º¥­¥ó¥º¥­¥ó¤È¿Ä¤«¤éÄˤà¤è¤¦¤Ë´¶¤¸¤ë¡£ºÇ¶á¤Ë¤Ê¤Ã¤ÆÁý°­¤ò´¶¤¸¤¿¤¿¤á¼õ¿Ç¤·¤¿¡£

½é¿Ç»þ¤ÎÆâÉþÌô¡§¤Ê¤·
¸½¾É¡§°ÂÀÅ»þVAS¤Ï35mm¡¢Æ°ºî»þ¤ÎVAS¤Ï80mm¡¢Ìë´Ö»þVAS¤Ï83mm¤Ç¤¢¤Ã¤¿¡£Ìë´ÖÄˤÎÉÑÅ٤ˤĤ¤¤Æ¤Ï¡ÖËèÆüɬ¤º¡×¡£Ìë´ÖÄˤÎÀ­¼Á¤Ï¡Ö¥º¥­¥ó¥º¥­¥ó¡×¡£¼ç´ÑŪ¤Ê¿ç̲¤Î¼Á¤Ï¡ÖÈó¾ï¤Ë°­¤¤¡×¤Ç¤¢¤Ã¤¿¡£

¾³Ð½ê¸«¡§¸ª´ØÀá²ÄÆ°°è¤ÏÁ°Êýµó¾å100ÅÙ¡¢³°Àû30ÅÙ¡¢ÆâÀûL5¥ì¥Ù¥ë¡¢XÀþ¸¡ºº¤Ç¤Ï¸ªÊö²¼¤Î¸²Ãø¤Ê¶¹¾®²½¤òǧ¤á¤ë¡£MRI¸¡ºº¤Ë¤ª¤¤¤ÆÛù¾å¶Ú秤ν¤ÉüÉÔǽÃÇÎö¤òǧ¤á¤¿¡£¿ÈÂν긫¤Ç¤Ï¸ª´ØÀáÁ°Êý¡¢±¨¸ýÆ͵¯¼þÊդ˰µÄˤòǧ¤á¤¿¡£NeerÍÛÀ­¡¢HawkinsÍÛÀ­¤Ç¤¢¤Ã¤¿¡£

Î×¾²¿ÇÃÇ¡§¼ê½ÑŬ±þ¤Î¤Ê¤¤ç§ÈÄÃÇÎö
·ì´É»£±Æ½ê¸«¡§Á°¾åÏÓ²óÀûÆ°Ì®¤è¤ê·ëÀá´Ö¹Â¼þ°Ï¤ª¤è¤ÓæþãÝǹ¤Ë°Û¾ï·ì´É¤òǧ¤á¤¿¡Ê¿Þ3¡Ë¡£

¼£ÎŸå·Ð²á¡§¼£ÎŸ壱¥ö·î´Ö¤ÏÌë´ÖÄˤ¬»ý³¤·¡¢¼£ÎÅ7½µ¸å¤ËÂçÉý¤Ê²þÁ±¤ò¼«³Ð¤·¤¿¡£Ìë´ÖÄËVAS¤Ï¼£ÎŸ壱½µ¡¢4½µ¡¢12½µ¡¢24½µ¤½¤ì¤¾¤ì¤Ë¤ª¤¤¤Æ67mm¡¢60mm¡¢11mm¡¢10mm¤Ç¤¢¤Ã¤¿¡£¼ç´ÑŪ¤Ê¿ç̲¤Î¼Á¤ÎÊѲ½¤Ï1½µ¸å¡¢4½µ¸å¤Ï¡Ö¾¯¤·²þÁ±¡×¼£ÎÅ12½µ¸å¡¢24½µ¸å¤Ï¡ÖÂçÉý¤Ë²þÁ±¡×¤Ç¤¢¤Ã¤¿¡£


±üÌîÀèÀ¸¤ÎÆüËܸìÏÀʸ¡¡¸ª¤ÎÌë´ÖÄˤؤΥ«¥Æ¡¼¥Æ¥ë¼£ÎÅ



¡Ú¹Í»¡¡Û

¸ª´ØÀá¼þ°Ï±ê¤Ë¸Â¤é¤º¡¢ËýÀ­Åª¤Ê¸ª´ØÀáÌë´ÖÄˤòÍ­¤¹¤ë´µ¼Ô¤Ë¤ª¤¤¤ÆÁªÂòŪư̮¤±Æ¤Î·ë²Ì¤«¤éÁ´Îã¤Ç°Û¾ï·ì´É¤¬´Ñ»¡¤µ¤ì¤¿¡£¤³¤ì¤é¤Î·ì´É¤Ï»£±Æ¾å¡Ö¥â¥ä¥â¥ä¡×¤È¤·¤¿¤è¤¦¤ÊÁü¤òÄ褷¡¢ÈùºÙ¤Ê·ì´É¤Î½¸¹ç¤Ç¤¢¤ë¤È¹Í¤¨¤é¤ì¤¿¡£·Ðư̮ŪÈù¾®·ì´ÉºÉÀòÎÅË¡¡ÊTMAE¡Ë¤ò»Ü¹Ô¤·¤¿·ë²Ì¡¢Ê¿¶Ñ¤ÎÌë´ÖÄËVAS¤Ï¼£ÎŸ壱½µ´Ö¤«¤é¸²Ãø¤ËÄã²¼¤·»Ï¤á¡¢24½µ¤Þ¤Ç·Ñ³¤·¤¿¡£áÖÄˤβþÁ±¤Ë¤È¤â¤Ê¤¤¿ç̲¤Î¼Á¤â²þÁ±¤µ¤ì¤¿¡£

Ìë´ÖÄˤε¡½ø¤Ï̤¤À¤ËÅý°ì¤µ¤ì¤¿¸«²ò¤¬ÆÀ¤é¤ì¤Æ¤¤¤Ê¤¤¡£Ëܸ¦µæ¤Î·ì´É»£±Æ½ê¸«¤Ç¤Ï¡¢¸ª´ØÀá¤ÎÌë´ÖÄˤò¤â¤Ä´µ¼ÔÁ´Îã¤Ë°Û¾ï·ì´É¤ÎÁýÀ¸¤òǧ¤á¡¢·ìήÁý²Ã¾õÂ֤Ǥ¢¤Ã¤¿¡£¤Þ¤¿ÈùºÙ¤Ê·ì´É¤òºÉÀò¤¹¤ë¤³¤È¤ÇáÖÄˤδËϤ¬ÆÀ¤é¤ì¤¿¤³¤È¤«¤é¡¢¤³¤ì¤é¤Î·ì´É¤¬Ìë´ÖÄˤÎÄˤ߻ɷã¤È²¿¤é¤«¤Î´Ø·¸¤¬¤¢¤ë¤³¤È¤¬¼¨º¶¤µ¤ì¤¿¡£

»ûÎÓ¤é¤Ïç§ÈÄÃÇÎö¤òÍ­¤¹¤ë´µ¼Ô47̾¤Ë¤Ä¤¤¤ÆĶ²»ÇÈ¿ÇÃÇÁõÃ֤Υɥåץ顼µ¡Ç½¤òÍѤ¤¤ÆÁ°¾åÏÓ²óÀûÆ°Ì®¤Î·ìή¤ò¬Äꤷ¤¿¤È¤³¤í¡¢½ÅÅÙ¤ÎÌë´ÖÄˤòÍ­¤¹¤ë¾ÉÎã¤Ë¤ª¤¤¤Æ¤ÏƱư̮¤Î¼ý½Ì´üºÇ¹â·ìή®ÅÙ¤¬Í¥°Ì¤ËÁý²Ã¤·¤Æ¤¤¤¿¤ÈÊó¹ð¤·¡¢´ØÀá¤ò±ÉÍܤ¹¤ë·ì´É¤Î·ìήÁý²Ã¤¬Ìë´ÖÄˤÎÉÂÂ֤˴ط¸¤·¤Æ¤¤¤ë¤Î¤Ç¤Ï¤Ê¤¤¤«¤È¹Í»¡¤·¤Æ¤¤¤ë10¡Ë¡£Ëܸ¦µæ¤Ç¡¢10ǯ°Ê¾å¤ÎËýÀ­Åª¤Ê·Ð²á¤ò¤¿¤É¤Ã¤¿¾ÉÎã¤Ë¤ª¤¤¤Æ¤â¡¢°Û¾ï·ì´É¤ÎÁýÀ¸¤È·ìήÁý²Ã¤È¤¤¤¦´ï¼ÁŪ¤ÊÊѲ½¤¬´Ñ»¡¤µ¤ì¤¿ÅÀ¤ÏÆäËÃíÌܤËÃͤ¹¤ë¤È¹Í¤¨¤ë¡£

Ìë´ÖÄˤΤߤʤ餺ËýÀ­áÖÄˤˤª¤¤¤Æ¤Ï¡¢ËýÀ­²½¤¹¤ì¤Ð¤¹¤ë¤Û¤É´ï¼ÁŪÊѲ½¤Î´óÍ¿¤¹¤ëÅٹ礤¤Ï¸º¾¯¤¹¤ë¤È¹Í¤¨¤é¤ì¤Æ¤¤¤ë¡£¤·¤«¤·Ëܸ¦µæ¤Î·ì´É»£±Æ¤Çǧ¤á¤é¤ì¤¿¤è¤¦¤Ê¡Ö¥â¥ä¥â¥ä¡×¤È¤·¤¿ÈùºÙ·ì´É¤ÎÁý¿£¤ÏÄ̾ï¤ÎMRI¤Ç¤Ï¸¡½Ð¤µ¤ìÆÀ¤Ê¤¤¤â¤Î¤Ç¤¢¤ê¡¢¤³¤ì¤Þ¤Ç¤Ëɾ²Á¤µ¤ì¤Æ¤³¤Ê¤«¤Ã¤¿¤È¸À¤¨¤ë¡£º£¸å¡¢Ìë´ÖÄˤΤߤʤ餺ËýÀ­áÖÄˤˤɤÎÄøÅÙ¤³¤Î¤è¤¦¤Ê·ì´É¤¬´Ø¤ï¤Ã¤Æ¤¤¤ë¤Î¤«¤Ï¸¡Æ¤¤¹¤ë²ÁÃͤ¬¤¢¤ë¤«¤â¤·¤ì¤Ê¤¤¡£

Ëܼ£ÎŤνüÄˤΥᥫ¥Ë¥º¥à¤ò¹Í»¡¤¹¤ë¤³¤È¤Ï¡¢Ìë´ÖÄˤε¡½ø¤Î²òÌÀ¤Ë¤â¤Ä¤Ê¤¬¤ë¤È¹Í¤¨¤ë¡£ÁÛÄꤷ¤¦¤ë¥á¥«¥Ë¥º¥à¤È¤·¤Æ¤Ï­¡±ê¾É·ì´É¤òºÉÀò¤·¤¿¤³¤È¤Ë¤è¤ë±ê¾É¾õÂ֤βþÁ±¡¢­¢Æ°ÀÅ̮ûÍí¤òºÉÀò¤·¤¿¤³¤È¤Ë¤è¤ëÁÈ¿¥¤Î»ÀÁÇË°ÏÂÅ٤βþÁ±¡¢­£ÉÂŪ¤Ê¾®·ì´É¤Î¼þ°Ï¤ËÁý¿£¤¹¤ë¿À·ÐÀþ°Ý¤«¤é¤Î¥·¥°¥Ê¥ë¸º¾¯¡¢¤Î£³¤Ä¤¬¹Í¤¨¤é¤ì¤ë¡£

­¡¤Ë¤Ä¤¤¤Æ¤À¤¬¡¢¸ª´ØÀá¼þ°Ï±ê¤ò»Ï¤á¡¢ËýÀ­áÖÄˤο¤¯¤Ç·ì´ÉÆ©²áÀ­¤Îж¿Ê¤ä±ê¾ÉºÙ˦¿»½á¤¬´Ñ»¡¤µ¤ì¤Æ¤ª¤ê3)¡¢±ê¾É·ì´É¤òºÉÀò¤¹¤ë¤³¤È¤Ç¶É½ê¤Î±ê¾ÉÄøÅÙ¤¬²þÁ±¤µ¤ì¤ë¤³¤È¤¬ÁÛÄê¤Ç¤­¤ë¡£

¼¡¤Ë­¢¤Ë¤Ä¤¤¤Æ¤À¤¬¡¢ËýÀ­Åª¤ÊáÖÄËÁÈ¿¥¤Ë¤ª¤¤¤Æ¤ÏË­É٤ʷì´ÉÁýÀ¸¤¬¸«¤é¤ì¤ë¤Ë¤â¤«¤«¤ï¤é¤ºÆý»ÀÃͤ¬¹â¤¤¤³¤È¤¬Êó¹ð¤µ¤ì2¡Ë¡¢Äã»ÀÁǴĶ­¤Ç¤¢¤ë¤È¹Í¤¨¤é¤ì¤Æ¤¤¤ë¡£¤Þ¤¿Ëܸ¦µæ¤Î·ì´É»£±Æ¤Ç¡¢17¸ªÃæ12¸ª¤Ë¤ª¤¤¤Æ¡¢Æ°Ì®¤«¤éÅêÍ¿¤·¤¿Â¤±ÆºÞ¤¬¶Ë¤á¤ÆÁá´ü¤ËÀÅÌ®¤ËήÆþ¤¹¤ë¸½¾Ý¡Êearly venous filling¡Ë¤òǧ¤á¤Æ¤ª¤ê¡Ê¿Þ£±¡Ý£³¡Ë¡¢¤³¤ì¤ÏÆ°ÀÅ̮ûÍí¤¬Â¸ºß¤¹¤ë¤³¤È¤Î»Øɸ¤È¤µ¤ì¤Æ¤¤¤ë¡£¤³¤Î¤¿¤á­¢¤Î¤è¤¦¤ËºÉÀòʪ¼Á¤ÎÅêÍ¿¤¬Æ°ÀÅ̮ûÍí¤òºÉÀò¤µ¤»¤ë¤³¤È¤Ç¡¢ÁÈ¿¥¤Î»ÀÁÇË°ÏÂÅÙ¤ò²þÁ±¤µ¤»¤Æ¤¤¤ë²ÄǽÀ­¤ÏÈÝÄê¤Ç¤­¤Ê¤¤¡£

¤µ¤é¤Ë­£¤Ë¤Ä¤¤¤Æ¤À¤¬¡¢¤³¤ì¤Þ¤Ç¤ËËýÀ­áÖÄˤÎÁÈ¿¥³ØŪ¸¡Æ¤¤Ë¤ª¤¤¤Æ¡¢¾®·ì´É¤ÎÃøÌÀ¤ÊÁý¿£¤È¤½¤ì¤é¤Î¾®·ì´É¤Ë¶áÀܤ¹¤ë¥µ¥Ö¥¹¥¿¥ó¥¹PÍÛÀ­¿À·ÐÀþ°Ý¤äCGRPÍÛÀ­¿À·ÐÀþ°Ý¤ÎÁý¿£¤¬Êó¹ð¤µ¤ì¤Æ¤­¤¿¡ÊÊÑ·ÁÀ­É¨´ØÀá¾É11¡Ë¡¢³°Â¦¾åðù±ê6)¡¢¹øÄÇÄÇ´Ö´ØÀá5)¡¢³Ü´ØÀá¾É16)¤Ê¤É¡Ë¡£Xu¤é¤Ï´ØÀáÊñ¤ÎÁÈ¿¥³ØŪ¤Ê¸¡Æ¤¤«¤é¡¢¸ª´ØÀá¼þ°Ï±ê¤Î´µ¼Ô¤Ç¤Ï¥³¥ó¥È¥í¡¼¥ë·²¤ÈÈæ³Ó¤·¤ÆÈùºÙ¤Ê·ì´É¡Êľ·Â¿ô½½¦Ìm¡Ë¤ÎÁý¿£¤È¡¢¤½¤Î¼þ°Ï¤Ë¤ª¤±¤ëPGP9.5ÍÛÀ­¿À·Ð¤ÎÁý¿£¤ä¿À·ÐÀ®Ä¹°ø»Ò¼õÍÆÂΤÎȯ¸½¾å¾º¤òÊó¹ð¤·¤Æ¤¤¤ë13)¡£¤Þ¤¿Gotoh¤é¤ÏÍ­ÄËÀ­¸ªç§ÈÄÃÇÎö´µ¼Ô¤Î¸ªÊö²¼³ê±ÕÊñ¤Ë¤ª¤¤¤Æ¡¢¾®·ì´É¤ÎÁý¿£¤È¼þ°Ï¤ËȼÁö¤¹¤ë¿À·ÐÀþ°Ý¤ÎÁý¿£¤òÊó¹ð¤·¤Æ¤¤¤ë4)¡£¤³¤ì¤é¤Î¿À·ÐÀþ°Ý¤«¤éáÖÄË¥·¥°¥Ê¥ë¤¬Á÷¤é¤ì¤Æ¤¤¤ë¤È²¾Äꤹ¤ë¤È¡¢Ëܸ¦µæ¤Î¾ÉÎã¤Î¤è¤¦¤ËÈæ³ÓŪÁᤤ¥¿¥¤¥ß¥ó¥°¤Ç½üÄˤ¬ÆÀ¤é¤ì¤ë¤³¤È¤Î¥á¥«¥Ë¥º¥à¤È¤Ê¤Ã¤Æ¤¤¤ë²ÄǽÀ­¤¬¤¢¤ë¡£

­¡¤«¤é­£¤Îµ¡½ø¤Î¤¦¤Á¤¤¤º¤ì¤«°ì¤Ä¤È¤¤¤¦¤è¤ê¤ÏÊ£¿ô¤¬½Å¤Ê¤Ã¤Æ¤¤¤ë¤³¤È¤â¹Í¤¨¤é¤ì¤ë¡£

ÆäˡÖÆüÃæ¤Ï¤µ¤Û¤ÉÄˤ¯¤Ê¤¤¤¬¡¢Ì뿲¤Æ¤¤¤ë´Ö¤ËÄˤ߽Ф¹¡×¤È¤¤¤¦¥¨¥Ô¥½¡¼¥É¤òÀâÌÀ¤¹¤ë¾ì¹ç¤Ë¡¢­¢¡¢­£¤Ï¼¨º¶¤ËÉ٤ࡣ´Ä¶­²¹¤Î¾å¾º¤Ë¤è¤Ã¤ÆÈéÉæ¤Ø¤Î·ìή¤Ï¿ôÇܤËÁý¤¨¤ë¤È¤µ¤ì15)¡¢±¿Æ°¤Ë¤è¤Ã¤Æ¶ÚÆù¤Ø¤Î·ìήÎ̤ϺÇÂç¤Ç£²£°¡Á£³£°ÇܤËÁý²Ã¤¹¤ë¤È¤µ¤ì¤Æ¤¤¤ë9)¡£È¿ÂФËÌë´Ö¤ÏÉÔÆ°¾õÂ֤Ȥʤê¶ÚÆù¤Ø¤ÎÀ¸ÍýŪ·ìή¤ÏÂçÉý¤Ë¸º¾¯¤·¡¢¤Þ¤¿ÈéÉæ¤ÎÀ¸ÍýŪ·ìή¤â¸º¾¯¤¹¤ë¤È¹Í¤¨¤é¤ì¤ë¡£¤³¤Î¤³¤È¤ÇÁêÂÐŪ¤Ë°Û¾ï·ì´É¤Î·ìή¤¬Áý²Ã¤¹¤ë¤³¤È¤ä¡¢¤¢¤ë¤¤¤ÏÆ°ÀÅ̮ûÍíÎ̤¬Áý²Ã¤·¤ÆÁÈ¿¥¤ÎÄã»ÀÁDz½¤¬½õŤµ¤ì¤ë¤Î¤«¤â¤·¤ì¤Ê¤¤¡£¤¤¤º¤ì¤Ë¤·¤Æ¤â²¾Àâ¤Ë²á¤®¤º¤µ¤é¤Ê¤ë´ðÁÃŪ¸¡Æ¤¤¬Ë¾¤Þ¤ì¤ë¡£

Ëܸ¦µæ¤Ë¤Ï¸Â³¦¤¬¤¢¤ë¡£°ÂÁ´À­¤äÍ­¸úÀ­¤ò¸¡Æ¤¤¹¤ë¤Ë¤Ï¾ÉÎã¿ô¤¬¶Ë¤á¤Æ¾¯¤Ê¤¤¡£¤Þ¤¿Â¾¼£ÎŤä¥×¥é¥·¥Ü¼£ÎŤȤÎÈæ³Ó¤¬¤Ê¤µ¤ì¤Æ¤¤¤Ê¤¤¡£¤è¤êÂ絬ÌϤÊÎ×¾²¸¦µæ¤äÈæ³Ó¸¦µæ¤¬º£¸å¤Ê¤µ¤ì¤ë¤³¤È¤¬µá¤á¤é¤ì¤ë¡£


¡Ú¤Þ¤È¤á¡Û
¿ôǯÍè»ý³¤¹¤ëáÖÄˤâ´Þ¤á¤Æ¡¢¸ª´ØÀá¤ÎÌë´ÖÄˤ˰۾ï·ì´É¤¬´ØÍ¿¤·¤Æ¤¤¤ë¤³¤È¤¬¼¨º¶¤µ¤ì¤¿¡£Èù¾®·ì´ÉºÉÀòÎÅË¡¤Ï¸ª´ØÀá¤ÎËýÀ­Åª¤ÊÌë´ÖÄˤËÂФ·¤Æ¸ú²ÌŪ¤Ê¼£ÎÅË¡¤È¤Ê¤ê¤¦¤ë¤³¤È¤¬¼¨º¶¤µ¤ì¤¿¡£




¡Úʸ¸¥¡Û
1) Aihara T. A Basic Study of Super-Selective Transcatheter Arterial Chemotherapy and Chemoembolization. (1). Establishment of an Animal Model for Super-selective Transcatheter Arterial Chemotherapy and Preparation for Appro-priate Suspension of Microembolization. Kawasaki Igakkaishi 25 (1999) 47-54.
2) Alfredson H, Bjur D, Thorsen K, Lorentzon R, Sandstrom P. High intratendinous lactate levels in painful chronic Achilles tendinosis. An investigation using microdialysis technique. J Orthop Res. 20 (2002) 934-938.
3) Costa C, Incio J, Soares R. Angiogenesis and chronic inflammation: cause or consequence? Angiogenesis. 10 (2007) 149-166.
4) Gotoh M, Hamada K, Yamakawa H, Inoue A, Fukuda H. Increased substance P in subacromial bursa and shoulder pain in rotator cuff diseases. J Orthop Res. 16 (1998) 618-621.
5) Gronblad M, et al : Silver impregnation and immunohistochemical study of nerves in lumbar facet joint plical tissue. Spine (Phila Pa 1976), 16 (1991) 34-38.
6) Ljung BO, Forsgren S, Friden J. Substance P and calcitonin gene-related peptide expression at the extensor carpi radialis brevis muscle origin: implications for the etiology of tennis elbow. J Orthop Res. 17 (1999) 554-559.
7) Okuno Y, Oguro S, Iwamoto W, Miyamoto T, Ikegami H, and Matsumura N. Short-term results of transcatheter arterial embolization for abnormal neovessels in patients with adhesive capsulitis: a pilot study. J Should Elbow Surg. (2014) [Equip ahead of print]
8) Rowe CR : The shoulder. Churchill Livingston, New York, 1988, pp131-154.
9)Rowell LB, Circulatory adjustments to dynamic exercise. Human Circulation Regulation During Physical Stress. Oxford University Press, New York, NY, 1986, pp213-256.
10) Terabayashi N, Watanabe T, Matsumoto K, Takigami I, Ito Y, Fukuta M, et al. Increased blood flow in the anterior humeral circumflex artery correlates with night pain in patients with rotator cuff tear. J Orthop Sci. (2014) [Equip ahead of print]
11) Walsh DA, Bonnet CS, Turner EL, Wilson D, Situ M, McWilliams DF. Angiogenesis in the synovium and at the osteochondral junction in osteoarthritis. Osteoarthritis Cartilage. 15(2007) 743-751.
12) Woodhams R, Nishimaki H, Ogasawara G, Fujii K, Yamane T, Ishida K et al. Imipenem/cilastatin sodium (IPM/CS) as an embolic agent for transcatheter arterial embolisation: a preliminary clinical study of gastrointestinal bleeding from neoplasms. Springerplus 2 (2013) 344. doi:10.1186/2193-1801-2-344
13) Xu Y, Bonar F, Murrell GA. Enhanced expression of neuronal proteins in idiopathic frozen shoulder. J Shoulder Elbow Surg. 21 (2012) 1391-1397.
14) »³Ëܵ¹¹¬¡§ç§ÈÄÃÇÎö´µ¼Ô¤ÎÌë´ÖÄˤˤĤ¤¤Æ¡½½ÑÁ°¡¦½Ñ¸å¤Î¸ªÊö²¼³ê±ÕÊñ°µ¤ÎÊѲ½¡½¡¥¸ª´ØÀá. 28 (2004) 2: 279-282.
15) »³ºêʸÉ× : Æ°ÀÅ̮ʭ¹ç¤ÈÇ®Êü»¶¥·¥¹¥Æ¥à. °æ¾å˧¸÷¤Û¤«ÊÔ, Âβ¹­¶ Âβ¹Ä´À᥷¥¹¥Æ¥à¤È¤½¤ÎŬ±þ, NAP, 2010, pp98-105.
16) Yoshida H, et al : The expression of substance P in human temporomandibular joint samples: an immunohistochemical study. J Oral Rehabil, 26 (1999) 338-344.
17) µÈÅÄÅ°¡§¤¤¤ï¤æ¤ëÊÑ·ÁÀ­´ØÀá¾É¤ÎáÖÄˤˤĤ¤¤Æ¡¥À°·Á³°²Ê2688¡Ë:745-752,1975.



¥Ú¡¼¥¸¤ÎÀèƬ¤ØÌá¤ë

  • Á°¤Îµ­»ö¤Ø
  • °ìÍ÷¤ËÌá¤ë
  • ¼¡¤Îµ­»ö¤Ø